Cargando…

Personalized treatment for hepatocellular carcinoma in the era of targeted medicine and bioengineering

Hepatocellular carcinoma (HCC) is a major global health burden, causing approximately 8.3 million deaths each year, and it is the third leading cause of cancer-related death worldwide, with a relative 5-year survival rate of around 18%. Due to the advanced stage of diagnosis in most patients, system...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Hang, Yang, Huayu, Mao, Yilei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198383/ https://www.ncbi.nlm.nih.gov/pubmed/37214451 http://dx.doi.org/10.3389/fphar.2023.1150151

Ejemplares similares

Editorial: Hepatocellular carcinoma: from personalized medicine to practical guidelines
por: El-Nakeep, Sarah, et al.
Publicado: (2023)

Tenofovir over Entecavir on Hepatocellular Carcinoma Prevention: Potential Mechanisms and Suitable Population
por: Huang, Yongfa, et al.
Publicado: (2022)

Patient-derived organoids: a promising model for personalized cancer treatment
por: Yang, Huayu, et al.
Publicado: (2018)

Letter Regarding “Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma”
por: Wang, Yinhan, et al.
Publicado: (2022)

Characterization of immune features and immunotherapy response in subtypes of hepatocellular carcinoma based on mitophagy
por: Wang, Yanan, et al.
Publicado: (2022)

Human Primary Epithelial Cell Models: Promising Tools in the Era of Cystic Fibrosis Personalized Medicine
por: Awatade, Nikhil T., et al.
Publicado: (2018)

A Single Nucleotide Mixture Enhances the Antitumor Activity of Molecular-Targeted Drugs Against Hepatocellular Carcinoma
por: Mao, Da, et al.
Publicado: (2022)

Quantitative definitions of prognostic indicators of resectable pancreatic cancer
por: Sun, Hang, et al.
Publicado: (2022)

Role of exosomes in hepatocellular carcinoma and the regulation of traditional Chinese medicine
por: Yao, Man, et al.
Publicado: (2023)

Natural products of medicinal plants: biosynthesis and bioengineering in post-genomic era
por: Guo, Li, et al.
Publicado: (2022)

Systematic analysis of the role and significance of target genes of active ingredients of traditional Chinese medicine injections in the progression and immune microenvironment of hepatocellular carcinoma
por: Wang, Chao, et al.
Publicado: (2023)

Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma
por: Berretta, Massimiliano, et al.
Publicado: (2016)

Intracellular Reduction-Responsive Molecular Targeted Nanomedicine for Hepatocellular Carcinoma Therapy
por: Ding, Lei, et al.
Publicado: (2022)

Immunotherapies for advanced hepatocellular carcinoma
por: Sun, Li-Yang, et al.
Publicado: (2023)

Knockdown of TANK-Binding Kinase 1 Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular-Targeted Drugs
por: Du, Fengxia, et al.
Publicado: (2022)

Identification of RASSF1A promoter hypermethylation as a biomarker for hepatocellular carcinoma
por: Xu, Gang, et al.
Publicado: (2020)

Investigations of nitazoxanide molecular targets and pathways for the treatment of hepatocellular carcinoma using network pharmacology and molecular docking
por: Khan, Shakeel Ahmad, et al.
Publicado: (2022)

Intratumoural microbiome can predict the prognosis of hepatocellular carcinoma after surgery
por: Sun, Lejia, et al.
Publicado: (2023)

Clinicopathologic and prognostic significance of regulatory T cells in patients with hepatocellular carcinoma: a meta-analysis
por: Sun, Lejia, et al.
Publicado: (2017)

Cost-Effectiveness of Frontline Treatment for Advanced Renal Cell Carcinoma in the Era of Immunotherapies
por: Li, SiNi, et al.
Publicado: (2021)

Transcriptomic analysis and 3D bioengineering of astrocytes indicate ROCK inhibition produces cytotrophic astrogliosis
por: O'Shea, Ross D., et al.
Publicado: (2015)

Management of intrahepatic recurrence after resection for hepatocellular carcinoma exceeding the barcelona clinic liver cancer criteria
por: Xu, Wei, et al.
Publicado: (2017)

Advances of Fibroblast Growth Factor/Receptor Signaling Pathway in Hepatocellular Carcinoma and its Pharmacotherapeutic Targets
por: Wang, Haijun, et al.
Publicado: (2021)

Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma
por: Jiang, Lei, et al.
Publicado: (2023)

The role of RNA modification in hepatocellular carcinoma
por: Feng, Qiang, et al.
Publicado: (2022)

Value of Quantitative and Qualitative Analyses of Circulating Cell-Free DNA as Diagnostic Tools for Hepatocellular Carcinoma: A Meta-Analysis
por: Liao, Wenjun, et al.
Publicado: (2015)

Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing
por: Liao, Wenjun, et al.
Publicado: (2016)

Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies
por: Galun, Danijel, et al.
Publicado: (2017)

Multiple Primary Malignancies in Patients With Hepatocellular Carcinoma: A Largest Series With 26-Year Follow-Up
por: Xu, Wei, et al.
Publicado: (2016)

Personalized medicine for pathological circadian dysfunctions
por: Skelton, Rachel L., et al.
Publicado: (2015)

Editorial: Computational intelligence in personalized medicine
por: Zhang, Yuanpeng, et al.
Publicado: (2022)

CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine
por: Lopes-Pacheco, Miquéias
Publicado: (2020)

Elucidating the mechanism behind and investigating the efficacy of Traditional Chinese Medicine and Traditional Tibetan Medicine in combination with standard therapeutics in hepatocellular carcinoma and cholangiocarcinoma in vitro
por: Suo, Huizhen, et al.
Publicado: (2022)

Erratum: Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma
por: Frontiers Production Office,
Publicado: (2023)

Computational and In Vitro Analysis of Plumbagin’s Molecular Mechanism for the Treatment of Hepatocellular Carcinoma
por: Wei, Yanfei, et al.
Publicado: (2021)

Genetic Biomarkers For Hepatocellular Carcinoma In The Era Of Precision Medicine
por: Duan, Jingxian, et al.
Publicado: (2019)

Genetic Polymorphisms and the Clinical Response to Systemic Lupus Erythematosus Treatment Towards Personalized Medicine
por: Barliana, Melisa Intan, et al.
Publicado: (2022)

OSlihc: An Online Prognostic Biomarker Analysis Tool for Hepatocellular Carcinoma
por: An, Yang, et al.
Publicado: (2020)

The role of NLRP3 inflammasome in hepatocellular carcinoma
por: Zhao, Huijie, et al.
Publicado: (2023)

Maprotiline Suppresses Cholesterol Biosynthesis and Hepatocellular Carcinoma Progression Through Direct Targeting of CRABP1
por: Zheng, Cancan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c192v7cusn8e0k0kkaibvel3rn